相似文献
1
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression.
Am J Hematol. 2021 Mar 1;96(3):E63-E65. doi: 10.1002/ajh.26062. Epub 2020 Dec 19.
2
Baseline serum B-cell maturation antigen levels predict time to disease progression for patients with smoldering multiple myeloma.
Eur J Haematol. 2021 Sep;107(3):318-323. doi: 10.1111/ejh.13666. Epub 2021 Jun 14.
3
New strategies for MGUS and smoldering multiple myeloma.
Clin Adv Hematol Oncol. 2004 Aug;2(8):507, 509.
4
Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma.
Blood Cancer J. 2018 Nov 8;8(11):107. doi: 10.1038/s41408-018-0144-x.
5
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998.
6
Reference change values of M-protein, free light chain and immunoglobulins in monoclonal gammopathy.
Clin Biochem. 2019 Dec;74:42-46. doi: 10.1016/j.clinbiochem.2019.09.004. Epub 2019 Sep 14.
7
Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used.
Leukemia. 2018 Aug;32(8):1815-1818. doi: 10.1038/s41375-018-0041-0. Epub 2018 Apr 20.
8
The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Clin Chem Lab Med. 2005;43(1):32-7. doi: 10.1515/CCLM.2005.004.
9
The cut-offs for kappa/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma.
Hematology. 2020 Dec;25(1):292-298. doi: 10.1080/16078454.2020.1802929.
10
Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
Blood Adv. 2018 Nov 27;2(22):3149-3154. doi: 10.1182/bloodadvances.2018024794.
引用本文的文献
1
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).
Res Sq. 2025 Jun 3:rs.3.rs-6696313. doi: 10.21203/rs.3.rs-6696313/v1.
2
The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma.
Hemasphere. 2024 May 6;8(5):e76. doi: 10.1002/hem3.76. eCollection 2024 May.
3
The consultant's guide to smoldering multiple myeloma.
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):551-559. doi: 10.1182/hematology.2022000355.
4
Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Cells. 2021 Dec 31;11(1):130. doi: 10.3390/cells11010130.
5
Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):673-681. doi: 10.1182/hematology.2021000304.
6
Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis.
Blood Cancer J. 2021 Nov 26;11(11):186. doi: 10.1038/s41408-021-00569-2.
7
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde.
Haematologica. 2021 Nov 1;106(11):2799-2812. doi: 10.3324/haematol.2021.278519.
本文引用的文献
1
Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
JAMA Oncol. 2019 Sep 1;5(9):1293-1301. doi: 10.1001/jamaoncol.2019.1568.
2
Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.
Blood Adv. 2018 Jun 26;2(12):1470-1479. doi: 10.1182/bloodadvances.2018016998.
3
Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression.
Leukemia. 2018 Jun;32(6):1427-1434. doi: 10.1038/s41375-018-0013-4. Epub 2018 Feb 2.
4
Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.
Blood Cancer J. 2016 Jul 29;6(7):e454. doi: 10.1038/bcj.2016.65.
5
Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial.
Lancet Oncol. 2016 Aug;17(8):1127-1136. doi: 10.1016/S1470-2045(16)30124-3. Epub 2016 Jul 9.
6
A multicentre study comparing two methods for serum free light chain analysis.
Ann Clin Biochem. 2013 May;50(Pt 3):255-61. doi: 10.1177/0004563212473447.
7
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Leuk Lymphoma. 2013 Oct;54(10):2215-8. doi: 10.3109/10428194.2013.764419. Epub 2013 Jul 29.
8
Smoldering multiple myeloma: natural history and recognition of an evolving type.
Br J Haematol. 2003 Nov;123(4):631-6. doi: 10.1046/j.1365-2141.2003.04654.x.
Zotero 插件